| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The specific molecular target of WAY-608119 is not definitively characterized in publicly available literature. As a drug derivative with a fused aromatic structure, it may interact with various biological targets, providing excellent ligand-binding potential to support drug discovery and lead optimization studies.
|
|---|---|
| ln Vitro |
In vitro data for WAY-608119 is limited. As a bioactive experimental molecule, it is primarily used as a research tool to explore signaling pathways. Its fused aromatic structure suggests potential for enzyme modulation and receptor binding, making it suitable for early-stage drug discovery screening campaigns.
|
| ln Vivo |
In vivo data for WAY-608119 is not available in the literature. As a research tool compound, it is primarily used in vitro for biochemical assays and pharmacological characterization rather than animal efficacy studies. Its in vivo properties would need to be evaluated if it were advanced as a lead compound.
|
| Enzyme Assay |
WAY-608119 is not typically used in standardized enzyme or receptor binding assays. As a biochemical research tool, standard protocols would depend on the specific experimental question. Quality control involves HPLC (≥98% purity) and LC-MS to confirm the molecular weight (223.23 g/mol) and formula (C13H9N3O).
|
| Cell Assay |
For cell-based assays, typical protocols involve seeding relevant cell lines in 96-well plates (5000-10000 cells/well), treating with WAY-608119 at concentrations ranging from 1-100 uM for 24-72 hours, and assessing viability via MTT or CellTiter-Glo. Alternatively, specific pathway activation can be measured by Western blot or reporter assays.
|
| Animal Protocol |
In vivo protocols for WAY-608119 have not been established, as it is primarily an in vitro research tool. If animal studies were to be conducted, typical xenograft or disease model protocols would involve administering the compound (oral or intraperitoneal) and monitoring relevant disease parameters.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data is publicly available for WAY-608119. As a research tool compound, its absorption, distribution, metabolism, and excretion properties have not been characterized. Researchers should conduct their own PK studies if needed for specific applications.
|
| Toxicity/Toxicokinetics |
No direct toxicity data is available for WAY-608119. As a research chemical, standard safety precautions should be taken when handling. Safety data sheets should be consulted for hazard information. The compound is supplied in powder form for research use only.
|
| Additional Infomation |
WAY-608119 is a bioactive molecule for research use only, not for therapeutic applications. Its mechanism of action has not been fully elucidated, and it serves primarily as a research tool for biochemical assays. This compound has not undergone clinical trials nor has it received regulatory approval. It is typically stored at -20degC as a powder and is stable for up to 3 years.
|
| Molecular Formula |
C13H9N3O
|
|---|---|
| Molecular Weight |
223.23
|
| Exact Mass |
223.075
|
| CAS # |
50362-93-1
|
| PubChem CID |
135412273
|
| Appearance |
Off-white to light brown solid powder
|
| LogP |
2.397
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
340
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)NC(=N2)C3=CN=CC=C3
|
| InChi Key |
WXCVPMGPMMEPBB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9N3O/c17-13-10-5-1-2-6-11(10)15-12(16-13)9-4-3-7-14-8-9/h1-8H,(H,15,16,17)
|
| Chemical Name |
2-pyridin-3-yl-3H-quinazolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4797 mL | 22.3984 mL | 44.7968 mL | |
| 5 mM | 0.8959 mL | 4.4797 mL | 8.9594 mL | |
| 10 mM | 0.4480 mL | 2.2398 mL | 4.4797 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
